Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
publication

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia


Wang, F. et al.
Nature Communications (2021)
Abstract

Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are major clinical issues. To understand the molecular underpinnings of clinical resistance to IDH inhibitors (IDHi), we perform multipronged genomic analyses (DNA sequencing, RNA sequencing and cytosine methylation profiling) in longitudinally collected specimens from 60 IDH1- or IDH2-mutant AML patients treated with the inhibitors. The analysis reveals that leukemia stemness is a major driver of primary resistance to IDHi, whereas selection of mutations in RUNX1/CEBPA or RASRTK pathway genes is the main driver of acquired resistance to IDHi, along with BCOR, homologous IDH gene, and TET2. These data suggest that targeting stemness and certain high-risk co-occurring mutations may overcome resistance to IDHi in AML.



Authors

Wang, F., Morita, K., DiNardo, C.D., Furudate, K., Tanaka,T., Yan, Y., Patel, K.P., MacBeth, K.J., Wu, B., Liu, G., Frattini, M., Matthews, J.A., Little, L.D., Gumbs, C., Song, X., Zhang, J., Thompson, E.J., Kadia, T.M., Garcia-Manero, G., Jabbour, E., Ravandi, F., Bhalla, K.N., Konopleva, M., Kantarjian, H.M., Futreal, P.A., Takahashi, K.



VIEW

publication
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O.
Cancer Cell (2021)
publication
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Thijssen, R.
Blood (2021)
publication
Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis
Dillon, L.W.
Blood Cancer Discovery (2021)
publication
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren, A.A.
Nature (2021)
REQUEST QUOTE